Shopping Cart
Your Cart is Empty
There was an error with PayPalClick here to try again
CelebrateThank you for your business!You should be receiving an order confirmation from Paypal shortly.Exit Shopping Cart

Michael P Gulseth Anticoagulation Consulting, Inc.

Specializing in professional consulting to aid hospitals and health-systems optimize patient outcomes when using anticoagulants and avoid litigation


Anticoagulation Therapy: a Clinical Practice Guide, 2nd Edition. American Society of Health-System Pharmacists

To order click here

Managing Anticoagulation Patients in the Hospital: the Inpatient Anticoagulation Service. American Society of Health-System Pharmacists

To order click here

2017 ISMP Medication Safety Self-Assessment for Antithrombotic Therapy

Most Recent Peer Reviewed Publications

Spinler SA, Gulseth, MP. Prevention and treatment of  COVID-19 related thrombosis.  In: Sanoski CA, Witt DM, eds.  Pharmacotherapy Self-Assessment Program, 2022 Book 2.  Current Issues in Pharmacotherapy.   Lenexa, KS: American College of Clinical Pharmacy, 2022: in press.

Dingus SJ, Smith AR, Dager WE, Zochert S, Nothdurft SA, Gulseth MP.  Comparison of managing factor Xa inhibitor to unfractionated heparin transitions by aPTT versus a treatment guideline utilizing heparin anti-Xa levels. Ann Pharmacother. Epub ahead of print 5/2/22.

Smith A, Dager WE, Gulseth MP. Current practices in transitioning hospitalized patients from rivaroxaban or apixaban to a continuous unfractionated heparin infusion: a retrospective review. Am J Health-Syst Pharm. 2020 Aug 20;77(Suppl 3):S59-S65.

Kaide CG, Gulseth MP. Current strategies for management of bleeding associated with direct anticoagulants and review of investigational reversal agents.  Jounral of Emergency Medicine.  2020: 58(2): 217-233.

Kido K, Lee JC, Hellwig T, Gulseth MP. Direct oral anticoagulants in the morbidly obese population for atrial fibrillation and venous thromboembolism treatment: a systematic review. Pharmacotherapy. 2020 Jan;40(1):72-83.

Zochert S, Gulseth MP, et al. Use of specific Anti-Xa levels in acute kidney injury to transition patients from oral factor Xa inhibitors to IV heparin infusion. Am J Health-Syst Pharm. 2019: 76: 505-11.

Byron M, Hellwig T, Zochert S, Gavozdea-Barna M, Gulseth MP. Successful use of laboratory monitoring to facilitate an invasive procedure for a patient treated with dabigatran. Am J Health-Syst Pharm. 2017; 74: 461-5.

Gulseth MP. Overview of direct oral anticoagulant therapy reversal. Am J Health-Syst Pharm. 2016; 73(10 Suppl 2): S5-S13.

Gulseth MP. Vitamin K antagonists, direct oral anticoagulants, and the rationale for reversal agents. Am J Health-Syst Pharm. 2016; 73(10 Suppl 2):S3-S4.

Barta AL, Nutescu EA, Thompson PA, Bussey HI, Gulseth MP. Time spent at extreme International Normalized Ratio values and time in therapeutic range: the relationship with major bleeding and thrombosis events. Am J Health-Syst Pharm. 2015; 72:1188-94.

Hellwig, T, Gulseth MP. Pharmacokinetic and pharmacodynamic drug interactions with new oral anticoagulants: what do they mean for patients with atrial fibrillation? Ann Pharmacother. 47: 1478-1487.

Smythe MA, Fanikos J, Gulseth MP, et al. Rivaroxaban: practical considerations for ensuring safety and efficacy. Pharmacotherapy. 2013; 33(11): 1223-1245.

Chen SY, Wu N, Gulseth MP, et. al. One-year adherence to warfarin treatment for venous thromboembolism in high-risk patients and its association with long-term risk of recurrent events. J Manag Care Pharm. 2013; 19(4):291-301.

Hellwig TR, Gulseth MP. Emerging oral options for the prevention and treatment of venous thromboembolism. Am J Health-Syst Pharm. 2013; 70:113-125.

Hellwig TR, Peitz GJ, Gulseth MP. High-dose argatroban for treatment of heparin-induced thrombocytopenia with thrombosis: A case report and review of laboratory considerations. Am J Health-Syst Pharm. 2012: 69: 490-5.

Fowler S, Gulseth MP, Renier C, Tomsche J. Inpatient warfarin: experience with a pharmacist-led anticoagulation management service in a tertiary care medical center. Am J Health-Syst Pharm. 2012: 69: 44-8.

Gulseth MP, Wittkowsky AK, Fanikos J, Spinler SA, Dager WE, Nutescu EA. Use of dabigatran etexilate in clinical practice: confronting challenges to improve safety and effectiveness. Pharmacotherapy. 2011; 31(12): 1232-1249.

November 2009 Dobesh PP, Wittkowsky AK, Stacy Z, Dager WE, Trujillo TC, Gulseth MP, et. al. Key articles and guidelines in the treatment of venous thromboembolism. Pharmacotherapy; 29(11): 1385 (full text published on-line).

Gulseth MP, Grice GR, Dager WE. Pharmacogenomics of warfarin: uncovering a piece of the warfarin mystery. Am J Health-Syst Pharm. 2009: 66: 123-33.

Gulseth MP, Michaud J, Nutescu EA. Rivaroxaban: an oral direct inhibitor of factor Xa. Am J Health-Syst Pharm. 2008; 65: 1520-9.

Gulseth MP. Applying quality measures and guidelines in the management of acute coronary syndrome and venous thromboembolism. J Managed Care Pharm. 2008; 4(6)(supplS-a): S2-S3.

Dager WE, Gulseth MP. Implementing pharmacist anticoagulation management in the inpatient setting. Am J Health-Syst Pharm. 2007; 64: 1071-1079.

November 2005 Schneider BL, Gulseth MP, Cusick M. et. al. A computer program for a pharmacy managed inpatient warfarin dosing service. Am J Health-Syst Pharm. 2005; 62: 2393-6.

Gulseth MP. Ximelagatran: an orally active direct thrombin inhibitor. Am J Health-Syst Pharm. 2005; 62: 1451-67.